Back to News
Market Impact: 0.3
Rapport Therapeutics Launches $350 Mln Stock And Convertible Notes Offerings; Stock Down
Source: Nasdaq
Healthcare & BiotechCredit & Bond MarketsCompany Fundamentals
Rapport Therapeutics commenced separate underwritten offerings of $200 million in common stock and $150 million in aggregate principal amount of convertible senior notes due 2032. The announcement describes a $350 million capital raise; pricing and use of proceeds were not provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target